Management of Acute Bronchitis with Wheezes
For acute bronchitis with wheezing in patients without underlying COPD or asthma, bronchodilators are not routinely recommended, as evidence shows no consistent benefit in reducing cough severity or duration. 1, 2
However, the clinical approach differs substantially based on whether the patient has underlying chronic lung disease:
For Patients WITHOUT Known COPD or Asthma
Bronchodilators should not be routinely prescribed for acute bronchitis, even when wheezing is present. 1
- Low-quality evidence from five adult trials (n=418) showed no significant reduction in daily cough scores or percentage of adults still coughing after seven days with beta-agonists (71% control vs 86% with treatment, not statistically significant). 2
- Two pediatric trials (n=134) found no benefits from oral beta-agonists in children without airflow restriction. 2
- Beta-agonists caused more adverse effects (tremor, shakiness, nervousness) with a number needed to harm of 2. 2
- The 2020 CHEST guidelines explicitly recommend against routine prescription of inhaled beta-agonists, inhaled anticholinergics, or inhaled corticosteroids for acute bronchitis. 1
Important Caveat
In retrospective studies, 65% of patients with recurrent "acute bronchitis" episodes actually had undiagnosed mild asthma. 1 If wheezing is present, consider whether this represents:
- First presentation of asthma (may benefit from bronchodilators)
- Acute exacerbation of undiagnosed asthma
- True acute bronchitis in a patient without reversible airflow obstruction
If symptoms worsen or persist beyond expected timeframe (typically 10 days), reassessment with targeted investigations should be considered, including peak flow measurements, chest x-ray, or spirometry to identify underlying asthma or other conditions. 1
For Patients WITH Known COPD or Chronic Bronchitis
The management changes completely when underlying chronic lung disease is present—bronchodilators become first-line therapy. 1
Acute Exacerbation of Chronic Bronchitis
Start with short-acting beta-agonists (salbutamol 2.5-5 mg or terbutaline 5-10 mg nebulized) OR anticholinergic bronchodilators (ipratropium bromide 0.25-0.5 mg nebulized) every 4-6 hours. 1
- If no prompt response to the first agent at maximal dose, add the other agent (combination therapy). 1
- For moderate exacerbations, either a beta-agonist OR anticholinergic alone may suffice. 1
- For severe exacerbations or poor response to monotherapy, use both agents together. 1
- Continue nebulized bronchodilators for 24-48 hours or until clinical improvement, then transition to metered-dose inhalers. 1
Add systemic corticosteroids: prednisone 30-40 mg daily for 7-14 days (or hydrocortisone 100 mg IV if oral route not possible). 1, 3
- Corticosteroids improve lung function, oxygenation, and shorten recovery time in acute exacerbations of chronic bronchitis. 3
- A 2-week course is as effective as 8 weeks with fewer side effects. 1
- Do NOT use theophylline for acute exacerbations—it has no benefit and significant risk of complications. 1
Stable Chronic Bronchitis with Persistent Cough
Ipratropium bromide is the preferred first-line agent for chronic cough in stable chronic bronchitis (Grade A recommendation). 1, 4
- Standard dosing: ipratropium 36 μg (2 inhalations) four times daily. 4
- Ipratropium reduces cough frequency, cough severity, and sputum volume. 4
- Short-acting beta-agonists should be used to control bronchospasm and may also reduce chronic cough (Grade A recommendation). 1
- Theophylline can be considered for persistent cough but requires careful monitoring due to narrow therapeutic index and drug interactions, especially in elderly patients. 1
For Patients WITH Known Asthma
Treat as an asthma exacerbation with beta-agonists plus systemic corticosteroids. 1
- Severity indicators: cannot complete sentences, respiratory rate >25/min, heart rate >110/min, peak flow <50% best. 1
- Treatment: oxygen plus oral corticosteroids plus nebulized beta-agonist (salbutamol 5 mg or terbutaline 10 mg) repeated every 4-6 hours. 1
- If inadequate response, add ipratropium bromide 500 μg to beta-agonist and consider hospital admission. 1
Common Pitfalls to Avoid
- Do not prescribe antibiotics routinely for acute bronchitis—they are not indicated unless bacterial superinfection develops or the patient has underlying chronic lung disease with purulent sputum. 1, 5
- Do not use expectorants—they lack proven efficacy for cough in both acute and chronic bronchitis. 1
- Do not confuse acute bronchitis with acute exacerbation of chronic bronchitis—the latter requires bronchodilators and corticosteroids, while the former does not. 1, 3
- In COPD patients, nebulizers should be driven by compressed air (not oxygen) if PaCO2 is elevated or respiratory acidosis is present, with supplemental oxygen given via nasal prongs at 1-2 L/min during nebulization. 1
- Ensure proper inhaler technique—many treatment failures result from inadequate drug delivery rather than medication ineffectiveness. 1
- In elderly patients receiving ipratropium, use a mouthpiece rather than face mask to avoid ocular complications and glaucoma exacerbation. 1